|Articles|October 1, 2014
Dana-Farber Leads Kadcyla ATEMPT Study in HER2-Positive Breast Cancer
Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.
Advertisement
Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Updates Safety Warnings for Common Chemotherapy Drugs
2
KTX-1001 Elicits Responses in Some With Multiple Myeloma
3
FDA Removes Use Limitation for Yescarta in Primary CNS Lymphoma
4
Real-World Data with Amtagvi Show High Response Rates in Advanced Melanoma
5